News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Joan Brunet: Raising awareness about Birt-Hogg-Dubé Syndrome
Photo taken from Joan Brunet/X
Oct 7, 2024, 16:16

Joan Brunet: Raising awareness about Birt-Hogg-Dubé Syndrome

Joan Brunet, General Director of the Catalan Institute of Oncology, shared on X:

“Raising awareness about Birt-Hogg-Dubé Syndrome and supporting cancer patients participating in the Oncotrail Race is a great initiative by BIHDA.”

Joan Brunet

Source: Joan Brunet/X

BIHDA Birt-Hogg-Dubé Syndrome cancer Joan Brunet OncoDaily Oncology Oncotrail Race
Special Coverage
Voices
Sep 4, 2025, 13:21
Bodour Salhia: Turning Ovarian Cancer Awareness into Action and Evidence-Based Hope
Celebrities
Sep 4, 2025, 13:08
Gordon Ramsay Reveals Skin Cancer Surgery and Urges Fans to Protect Their Skin
Science
Sep 4, 2025, 12:51
Siddharth Sreemahadevan: PSMA PET/CT in Staging of Prostate Cancer – Gamechanger or Hype?
Voices
Sep 4, 2025, 12:46
Haig Aghajanian: The End of My Chapter with Capstan
Voices
Sep 4, 2025, 12:37
A Legacy will be Forged Through the New Richard Scolyer Chair in Brain Cancer - Mark Hughes Foundation Centre for Brain Cancer Research
Voices
Sep 4, 2025, 12:26
Bogda Koczwara: Misdiagnoses, Financial Burden and Barriers in Rare Cancer Care in Australia
Voices
Sep 4, 2025, 12:10
Raymond Chan: Cancer Australia’s Vision for An Integrated Cancer Care Navigation System
Voices
Sep 4, 2025, 11:57
Enhancing Patient Understanding of Cancer Treatment Impacts on Quality of Life - Common Sense Oncology
Voices
Sep 4, 2025, 11:39
Lacy Hubbard: Honored to Join the RSOG 11th Annual Scientific Conference
Voices
Sep 4, 2025, 09:26
Kevin Lo: A Touch of Pink for a Powerful Purpose
Science
Sep 4, 2025, 09:19
Elisa De Paolis: NRG1 VUS Network Analysis and Prognostic Role in EGFR-Mutant NSCLC
FDA Approvals
Sep 4, 2025, 09:08
FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC